Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Coleman Gross

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Urologic Nursing|August 7, 2007
The effects of sleep-disordered breathing symptoms on voiding patterns in stroke patientsFrances Hardin-Fanning, Jan Coleman Gross
Journal of Molecular Endocrinology|April 10, 2004
Cinnamic acid based thiazolidinediones inhibit human P450c17 and 3beta-hydroxysteroid dehydrogenase and improve insulin sensitivity independent of PPARgamma agonist activityWeibke Arlt, Partha Neogi, Coleman Gross, et al.
Obesity (Silver Spring, Md.)|March 27, 2010
Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal menColeman Gross, Christine M Blasey, Robert L Roe, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|August 15, 2018
Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS InhibitorsRobert A Kloner, Coleman Gross, Jinwei Yuan, et al.
Urologic Nursing|August 7, 2007
Effect of time of day for urinary catheter removal on voiding behaviors in stroke patientsJan Coleman Gross, Frances Hardin-Fanning, Mary Kain, et al.
The Journal of Clinical Endocrinology and Metabolism|July 12, 2014
Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing's disease during long-term treatment with the glucocorticoid receptor antagonist mifepristoneMaria Fleseriu, James W Findling, Christian A Koch, et al.
Clinical Endocrinology|October 10, 2013
Global clinical response in Cushing's syndrome patients treated with mifepristoneLaurence Katznelson, D Lynn Loriaux, David Feldman, et al.
Advances in Therapy|November 6, 2009
Mifepristone treatment of olanzapine-induced weight gain in healthy menColeman Gross, Christine M Blasey, Robert L Roe, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|January 23, 2013
A new therapeutic approach in the medical treatment of Cushing's syndrome: glucocorticoid receptor blockade with mifepristoneMaria Fleseriu, Mark E Molitch, Coleman Gross, et al.
The Journal of Clinical Endocrinology and Metabolism|April 3, 2012
Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndromeMaria Fleseriu, Beverly M K Biller, James W Findling, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Urologic Nursing|August 7, 2007
The effects of sleep-disordered breathing symptoms on voiding patterns in stroke patientsFrances Hardin-Fanning, Jan Coleman Gross
Journal of Molecular Endocrinology|April 10, 2004
Cinnamic acid based thiazolidinediones inhibit human P450c17 and 3beta-hydroxysteroid dehydrogenase and improve insulin sensitivity independent of PPARgamma agonist activityWeibke Arlt, Partha Neogi, Coleman Gross, et al.
Obesity (Silver Spring, Md.)|March 27, 2010
Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal menColeman Gross, Christine M Blasey, Robert L Roe, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|August 15, 2018
Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS InhibitorsRobert A Kloner, Coleman Gross, Jinwei Yuan, et al.
Urologic Nursing|August 7, 2007
Effect of time of day for urinary catheter removal on voiding behaviors in stroke patientsJan Coleman Gross, Frances Hardin-Fanning, Mary Kain, et al.
The Journal of Clinical Endocrinology and Metabolism|July 12, 2014
Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing's disease during long-term treatment with the glucocorticoid receptor antagonist mifepristoneMaria Fleseriu, James W Findling, Christian A Koch, et al.
Clinical Endocrinology|October 10, 2013
Global clinical response in Cushing's syndrome patients treated with mifepristoneLaurence Katznelson, D Lynn Loriaux, David Feldman, et al.
Advances in Therapy|November 6, 2009
Mifepristone treatment of olanzapine-induced weight gain in healthy menColeman Gross, Christine M Blasey, Robert L Roe, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|January 23, 2013
A new therapeutic approach in the medical treatment of Cushing's syndrome: glucocorticoid receptor blockade with mifepristoneMaria Fleseriu, Mark E Molitch, Coleman Gross, et al.
The Journal of Clinical Endocrinology and Metabolism|April 3, 2012
Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndromeMaria Fleseriu, Beverly M K Biller, James W Findling, et al.
Pageof 2